Innate Immunotherapeutics Limited (ASX Code:IIL) has today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2016.
The cash balance as at 30 June 2016 was $1,024,000, a decrease of $2,177,000 from the end of the previous quarter.
Net cash usage for the three months was $2,194,000 of which $1,584,000 related to research and development, being principally the Company's Phase 2B trial of MIS416 in patients with secondary progressive multiple sclerosis (SPMS). This trial has now fully enrolled 93 patients and should be completed in April 2017. A substantive initial report is expected about four months later.
For further information please download PDF attached:
Download this document
